Get the (IMDC) Report Here
Trade with Jim Cramer 14 Days FREE
The company lost its bid for Inamed and posted a weak quarter, but its deal for Reloxin's a real coup.
The company buys the rights to an experimental Botox-like drug.
Two readers figured out the options trading around this deal.
We've got 45 minutes to answer three questions about options trading around this deal.
Allergan moves a step closer.
Genomic Health shares get hammered after a downgrade.
Cramer says the fat-fighting craze offers several good stock plays.
The company also misses estimates for the third quarter.
The exchange offer was scheduled to expire Tuesday but will now end Feb. 22.
Net sales exceeded expectations, coming in at $594.9 million.
The deal is still waiting for clearance from the U.S. Federal Trade Commission.
Cramer says there's money to be made from the boomer generation's quest for artificial youth .
Medicis withdrew its agreement to buy Inamed and received a $90 million break-up fee.
The company says it will get a $90 million break-up fee.
However, the company's directors say Allergan's offer is superior to the proposal from Medicis.
Medtronic and Nastech are among a host of players aiming to cut obesity rates.
The company tells Inamed to reject Allergan's offer or prepare to pay up.
There's a new twist in the tale of Botox and breast implants.
Medicis rejects the offer.
If Inamed goes with Allergan, he says his firm won't rethink its business strategy.
Who made what calls.
It directs management to evaluate the offer.
The company offers $3.2 billion.
We're close to a more lasting rally, but be aware of recent technical damage.
The company could soon join rival Mentor in selling silicone gel breast implants.
The company hopes a fat-fighting device can give it more heft.
The Arms Index numbers still indicate that a short-term rally -- only for the nimble -- is almost upon us.
But the company says first-quarter earnings beat estimates.
Neither the agency nor the company would provide details on the conditions imposed by the FDA.
The company reported fourth-quarter results that exceeded analysts' estimates.
©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.